Introduction
GVHD is a significant complication of allogeneic hematopoietic stem cell transplantation (HSCT). The mortality rate of steroid refractory or recurrent GVHD remains greater than 70%. Second-line therapies such as antithymocyte globulin, high-dose steroids, or monoclonal antibodies have failed to improve outcome. [1] [2] [3] [4] Novel immunosuppressive agents are still needed to treat acute GVHD.
Many clinical manifestations of GVHD are due to the dysregulated production of cytokines by alloreactive donor T cells. 5 Tumor necrosis factor-a (TNF-a) is a proinflammatory cytokine released from tissue damage caused by pretransplant conditioning agents. Overproduction of TNF-a by activated macrophages and T cells upregulates the expression of MHC antigens, endothelial cell and leukocyte adhesion molecules and directly mediates cellmediated cytotoxicity seen in acute GVHD. 5, 6 The resultant recruitment of effector cells directly mediates cell-mediated cytotoxicity and amplifies the process by further stimulation of donor T cells. In several donor-recipient murine strain combinations, increased TBI dosing has been associated with more severe gut damage and higher GVHD severity, along with higher systemic TNF-a levels. 7 Target organ damage and mortality were reduced by infusions of anti-TNF-a antibodies. In a prospective study of 111 allogeneic SCT recipients, increased serum TNF-a levels correlated with increased GVHD severity and transplantrelated mortality. 8 Following infusion of a chimeric murine IgG 1 TNF-a monoclonal antibody, B-C7, 17 of 24 patients with steroid-refractory, grade III-IV GVHD experienced partial responses; however GVHD recurred in most patients within a median of 3 days after discontinuation. 9 These earlier studies suggested that modulation of TNF-a may need to be sustained and combined with other agents to maximize effectiveness.
Infliximab (REMICADE, Centocor, Malvern, PA, USA) is a murine-human chimeric IgG1k monoclonal antibody that binds with high affinity to the soluble and transmembrane forms of TNF-a, and inhibits their binding with the cellular receptors. 10 Clinical trial results in rheumatoid arthritis (RA) following a single dose (1 mg/kg) of infliximab showed a sharp and substantial decline in the levels of two important acute-phase proteins, C-reactive protein and IL-6, supporting a potent pharmacological effect of infliximab in blocking TNF-a and reducing inflammation.
Several retrospective case series have suggested efficacy of infliximab in the treatment of GVHD. [12] [13] [14] [15] [16] [17] [18] Only a small number of pediatric patients have been reported. We review our experience with infliximab treatment of 24 children with steroid-resistant GVHD.
Patients and methods
A Pediatric Blood and Marrow Transplant Consortium (PBMTC) survey was undertaken in early 2002 to capture information about current clinical practice using infliximab in children with GVHD to plan a prospective infliximab clinical trial. MD Anderson Cancer Center (Houston, TX, USA) and Children's Mercy Hospital (Kansas City, MO, USA) were identified as having the most experience in this clinical setting. Subsequently, a retrospective chart review of all consecutive pediatric cases of acute and chronic GVHD treated with infliximab between December 1998 and October 2001 at these two institutions was performed. Clinical manifestations of GVHD, GVHD therapy, infections and organ function before and after infliximab treatment were assessed. Duration of survival and causes of death were identified. Additional children have received infliximab as GVHD therapy since 2001; however, the cutoff date was chosen at the time of the review.
The patients had received BM, PBSC or cord blood (CB) grafts from related (n ¼ 4) or unrelated (n ¼ 20) donors. All patients had failed to respond adequately to 2 mg/kg/day methylprednisolone. Almost half of the patients had failed additional GVHD treatment (Tables 1 and 2) .
Definitions
Staging and grading of acute GVHD were according to the modified Glucksberg criteria. 19 GVHD was considered acute if it occurred within the first 100 days after allogeneic HSCT. Chronic GVHD diagnosis and staging were based on standard criteria. 20 GVHD was steroid-resistant when it failed to respond to or progressed while receiving 2 mg/kg/ day methylprednisolone. Infliximab response was judged based on each patient's first course of infliximab treatment. Invasive fungal infections (IFI) were defined by the 2002 European Organization for Research and Treatment of Cancer (EORTC)/National Institute of Allergy and Infectious Diseases (NIAID) international consensus criteria. 21 
Infliximab treatment
Infliximab, generally 10 mg/kg/dose, was administered intravenously over 1-2 h. No premedication was routinely administered. Infliximab was repeated weekly for a median of four doses for patients with acute GVHD (range: 1-58) and 26 doses for patients with chronic GVHD (range: 5-162). Two patients with severe protein-losing enteropathy received 10-15 mg/kg/dose infliximab up to three times per week. Steroids were tapered based on clinical judgement following signs of clinical improvement. Six patients received additional treatment with infliximab for GVHD recurrence.
Response evaluation GVHD responses were based on the maximal response within 56 days after starting infliximab.
For acute GVHD, responses were assessed for each involved organ. Complete response (CR) indicated resolution of organ involvement. Partial response (PR) was defined as a decrease in the severity of organ involvement by at least 1 stage without deterioration in another organ. No response (NR) was a lack of change in the organ staging. Progressive disease (PD) reflected an increase in organ staging.
Overall response for acute GVHD was defined as follows: CR indicated resolution of all clinical manifestations of GVHD. PR was defined as a decrease in the severity of GVHD by at least 1 grade without worsening of any organ. A mixed response (MR) indicated that one or more organs improved, while another organ progressed. No response (NR) was a lack of change in the GVHD staging. Progressive disease (PD) reflected worsening of GVHD by at least 1 grade.
For chronic GVHD, CR was defined as resolution of signs and symptoms in all involved organs. PR was defined as significant clinical improvement in at least one involved organ. NR was a lack of improvement or worsening in GVHD manifestations. In addition, organ-specific responses were documented.
Patients were evaluable for infusion-related toxicities at any time after the initiation of infliximab. Patients were All confidence levels reported are at a level of 95%.
Results

Patient characteristics
The median age was 5 years (range: 0.3-18). Eighteen subjects (75%) were less than 10 years of age. The patients had received BM, PBSC or CB grafts from related (n ¼ 4) or unrelated (n ¼ 20) donors. Eighteen patients received infliximab therapy for manifestations of acute GVHD, while six patients were initially treated for extensive cGVHD. Grade of acute GVHD present when infliximab therapy started was:
and IV (n ¼ 6). Table 1 summarizes patient characteristics, while  Table 2 Five of 16 evaluable patients treated for acute GVHD had complete responses of at least 3 months duration after a median of four doses. Only two of these responses were sustained long term. Six patients treated for acute GVHD received additional infliximab therapy for GVHD recurrence. Recurrences typically occurred during steroid tapering or after discontinuation of infliximab.
Chronic GVHD responses
Six patients (UPN 19-24) received infliximab for extensive chronic GVHD that was refractory to multiple immunosuppressive agents. All had concurrent manifestations of acute GVHD as well. Two patients who initially received infliximab for acute GVHD were retreated months later for manifestations of cGVHD. Infliximab was initiated at a median of 269 days (range: 215-479) after transplant.
Eighty three percent of cases responded; however, responses were usually partial and were not sustained longterm. GI, oral and cutaneous manifestations were most likely to respond.
Predictors of GVHD response and survival
Univariate analysis for GVHD response after infliximab was performed. Age above or below 10 years, sex, donor type (MSD vs MUD/MMRD) and stem cell source (BM, PBSC vs cord) showed no statistical correlation with response to infliximab. There was a trend for response based on GVHD severity, with Grade I-II GVHD being more responsive to infliximab (P ¼ 0.07).
Univariate analysis of predictors for prolonged survival after initiation of infliximab for GVHD were analyzed, including best response (CR/PR vs other), acute GVHD grade I-II vs III-IV vs chronic GVHD, primary cause of death, donor type (MSD vs MMRD/MUD) and stem cell source (BM vs PBSC vs cord). Achieving a complete or partial response to infliximab was found to be the only factor predictive of prolonged survival (P ¼ 0.05).
Toxicity
A median of eight (range: 1-162) doses were given to 24 patients (Table 2) . No infusion-related events occurred despite multiple doses of infliximab. Neither neurologic nor cardiac complications attributed to infliximab were detected in any patient, in spite of prolonged infliximab treatment in some patients (X25 doses in five patients). No case of second malignant neoplasms or post-transplant lymphoproliferative disease occurred.
Even with aggressive antimicrobial prophylaxis, infections were the most significant complications encountered and were a contributing cause of death in 11/24 (46%) cases. Only 2 of 22 (9%) evaluable patients had no documented infections within 100 days of the final dose of infliximab. No proven cases of tuberculosis or atypical mycobacterium were noted.
Twenty-five documented bacterial infections occurred. The most common site was the blood stream (70%), while the remaining infections were found in the respiratory (9%) or the gastrointestinal tract (22%). The predominance of Gram-positive bacteremia was likely related to longstanding central venous access devices in these patients. Two cases of bacterial sepsis proved fatal. Viral infections occurred in 7/22 evaluable patients (32%). Two cases of CMV reactivation resolved with ganciclovir without clinical manifestation of CMV disease. One patient died from disseminated adenovirus infection. There were three cases of proven or possible IFI.
Outcomes
The median survival of the 22 evaluable children was 308 days. Survival for these high-risk children with steroidresistant GVHD was as follows: 67% at 6 months, 46% at 12 months, 25% at 18 months, 21% at 24 months, and 13% beyond 36 months. Relapse was the cause of death for five patients, but three of these patients were in relapse before infliximab treatment. Other causes of death were GVHD (n ¼ 7), infection (n ¼ 7), pulmonary hemorrhage (n ¼ 4) and multiorgan failure (n ¼ 1). One patient remains alive and leukemia-free 1530 days after transplant while receiving tacrolimus and low-dose steroids for broncholitis obliterans.
Pulmonary hemorrhage was a contributing cause of death for 7/22 (32%; CI ¼ [14%, 55%]) patients, six of whom had refractory, extensive cGVHD. All cases were p5 years of age (range: 1.5-5 years). Five patients had partial responses to infliximab. The remaining two patients' GVHD was unresponsive to infliximab when pulmonary hemorrhage occurred. Hemorrhage was accompanied by thrombocytopenia in 5/7 cases. Three cases were associated with thrombotic microangiopathy. Two cases occurred in close proximity to Gram-negative bacteremia. Other previously described risk factors for pulmonary hemorrhage after transplant 22, 23 noted in these cases included total body irradiation (n ¼ 4), busulfan (n ¼ 2), multiorgan failure (n ¼ 1) and Hurler syndrome (n ¼ 1). All episodes of pulmonary hemorrhage proved fatal at a median of 454 days (range, 186-1305) after transplant.
Discussion
This case series details the use of infliximab for treatment of severe acute and chronic GVHD in children. It represents the largest pediatric experience reported to date. It was an efficacious agent for GVHD, particularly for those children with GVHD involvement of the skin and intestinal tract. The overall response rate to infliximab was 82%, with 12 patients (55%) achieving a complete response. Only 2 (9%) patients showed no response to infliximab. Infliximab was well tolerated even when many doses were given.
Impressive responses to infliximab have been reported for refractory GVHD, especially for skin and GI involvement. Our experience with infliximab dosing is similar to that in other retrospective reports (Table 3) . In these reports, the infliximab dose administered was 10 mg/kg/ dose weekly Â 4, with the exception of 5 mg/kg weekly Â 3 used by Yamane et al. 17 Among these published reports, only three children were described, all of whom responded but eventually died (relapse, GVHD/aspergillosis and GVHD, respectively). Our larger experience in pediatric patients confirmed the results of these reports.
Although infliximab was approved by the Food and Drug Administration for treatment of inflammatory bowel disease at a dose of 5 mg/kg, the dose commonly employed in adults with GVHD is 10 mg/kg per week for at least 4 weeks. Our reasons for choosing this 10 mg/kg dose included (1) acute GVHD may be more similar to systemic juvenile rheumatoid arthritis for which 10 mg/kg had been used, and (2) concern for severe protein-losing enteropathy described previously in patients with severe GVHD of the gut. 24 When these patients were treated, no published data existed regarding the pharmacokinetics of TNF-a antagonist for treatment of GVHD. However, Sleight et al. 25 recently reported prospective clinical trial PK results in five children with biopsy-proven GVHD involving the gastrointestinal following a single 5 mg/kg dose of infliximab. Trough infliximab concentrations were reached a mean of 23 days following a single dose of infliximab (median 28 days, range: 7-33). In four of five subjects, infliximab concentrations greater than the targeted threshold level were maintained for at least 14 days.
In our experience, infliximab enabled steroid tapering in responding patients. Infliximab was useful for GVHD control in patients at extremely high risk of relapse, those with concurrent relapse and GVHD, and those with preexisting life-threatening infections for which steroids were relatively contraindicated. As successfully used in patients with inflammatory bowel diseases, [26] [27] [28] [29] repeated and sometimes prolonged courses of infliximab proved beneficial for several children in our series, and enabled steroid tapering. In Crohn's disease, 42% of the enrolled patients were infliximab-dependent, defined as relapse of symptoms requiring re-infusions of infliximab for disease control. Escalating the infliximab dose from 5 to 10 mg/kg in children prone to exacerbations while on maintenance therapy led to improved disease control, and enabled steroid tapering. Two patients in our series received prolonged high-dose infliximab therapy (162 and 157 doses, respectively) due to GVHD-related severe protein-losing enteropathy, as evidenced by their requirement of weekly g-globulin replacement instead of the typical monthly dosing to maintain normal IgG levels. Their diarrhea was repeatedly exacerbated with attempts to wean infliximab. In one case, the serum infliximab concentration measured 48 h following administration of a series of 10 mg/kg doses of infliximab was only 4 mg/ml. No antibodies against the drug were detectable. Therefore this child's infliximab halflife was notably shorter than in adults with active Crohn's disease in whom the median steady-state serum concentration was stable at 47 mg/ml, and their median concentration of infliximab 12 weeks after the final infusion was still 2.2 mg/ml. 29 In this prospective study, infliximab retreatment every 8 weeks maintained serum infliximab concentrations above 2 mcg/ml, controlled disease and was well tolerated with a low incidence of immunogenicity. We conclude that weekly dosing of infliximab may not be the most efficacious regimen for GVHD for all patients. Ongoing production of high amounts of TNF-a by donor T cells during GVHD may warrant maintaining higher infliximab concentrations for patients with severe GVHD involving the gut. Sustained cytokine blockade may optimize GVHD control, as suggested by previous investigators. [7] [8] [9] Prospective clinical trials are needed to define optimal dosing regimens and to document infliximab pharmacokinetics in stem cell transplant patients with GVHD and severe protein-losing enteropathy.
Consistent GVHD response rates following infliximab have been shown among other retrospective studies, [12] [13] [14] [15] [16] [17] [18] and are similar to a number of agents tested in the setting of refractory GVHD. As with the other cytokine-specific agents (e.g., anti-IL-2, anti-IL-1), the mechanism of action for infliximab is blockade of a single known mediator of GVHD. Neither infliximab nor these other agents directly affect the T cells underlying the GVHD; therefore GVHD is not eradicated. GVHD reactivation must be anticipated following discontinuation of anti-cytokine therapy, manipulation of other components of the treatment plan, or when GVHD triggers such as viral and bacterial infections are encountered. The same reactivation phenomenon occurs in (12) 4 (57) 2 (28) 1 (14) 0/4 0/4 4 (100)
Daclizumab (50) Tacrolimus (46) ECP (18) PUVA (8) ATG (50) MMF (54) CsA (15) 38% (8 CsA/FK506 (100) Pentostatin (27) PUVA (18) ATG (18) MMF (55) Daclizumab (27) Copaxone (9) 18% (24 other chronic autoimmune diseases such as Crohn's and rheumatoid arthritis. Maintenance therapy using infliximab has been proven beneficial in randomized clinical trials for these diseases. [26] [27] [28] [29] Future prospective clinical trials should address the safety and efficacy of these anti-cytokine modalities for GVHD maintenance therapy. To optimize the clinical benefits of these newer agents, incorporation of PK/PD study aims may lead to the most efficacious maintenance regimen(s) for GVHD. In addition, medical advancements that enable earlier detection and more effective control of infections, particularly fungal infections, should indirectly result in more durable GVHD control, improved quality of life and overall survival.
TNF blockade has been associated with an increased susceptibility to infection. In clinical trials for Crohn's disease and rheumatoid arthritis, treated infections were reported in 36% of infliximab-treated patients (average of 53 weeks of follow-up) and in 28% of placebo-treated patients. 24 Our patient population was more severely immunocompromised due to the combination of their primary disease and its therapy, exposure to numerous immunosuppressive agents and ongoing GVHD. Therefore it is not surprising that infection was common among our patients.
Allogeneic HSCT, whether complicated by GVHD or not, has been associated with a 15-20% incidence of IFI. [30] [31] [32] However, the incidence of invasive aspergillosis and other IFIs may have risen recently resulting from use of transplantation for older individuals, extended survival, prophylactic and empiric use of ultra-potent broadspectrum antibacterial and anti-fungal agents. [33] [34] [35] Marty et al. 36 retrospectively analyzed whether infliximab use in adults with severe GVHD was associated with a higher risk for non-Candidal IFI. Documented or probable IFI occurred in 10/53 (19%) patients, predominantly aspergillus. Five of eleven (45%) infliximab recipients developed an IFI as compared to 5/42 (12%) not exposed to the drug. However, the patient groups being compared differed in their incidence of severe GVHD involving the gut, stem cell source, conditioning, as well as their GHVD prophylaxis and therapy. Therefore, it is difficult to ascertain the contribution of infliximab to the development of IFI. Couriel et al. 18 reported that 6 of 21 (29%) adults treated with infliximab for GVHD suffered aspergillosis. These patients required at least one additional salvage immunosuppressive therapy due to infliximab resistance. In our pediatric series of severe, acute and chronic GVHD treated with infliximab, only 3/22 (13.6%) evaluable children developed proven or possible IFI. Youth, lack of nonmyeloablative conditioning, lower incidence of severe gut GVHD and more aggressive anti-fungal prophylaxis may contribute to this lower incidence of IFI. Undoubtedly, intensive antifungal prophylaxis is warranted in this highrisk patient population.
Keane et al. 37 reported the rate of tuberculosis (TB) reactivation among patients with RA in the United States who had received infliximab within the previous year to be four times higher than baseline. In our series as well as in the 138 GVHD cases reported previously using X10 mg/ kg/week infliximab, generally in combination with other immunosuppressive agents, no cases of TB reactivation were noted.
An interesting observation noted in this cohort of patients was the frequency and severity of pulmonary hemorrhage, a contributing cause of death for 7/22 (32%) evaluable patients. The majority of these patients received infliximab for refractory chronic GVHD. This incidence of pulmonary hemorrhage is significantly higher than the 7.9% incidence reported previously in patients with grades II-IV acute GVHD, 22 but may be purely anecdotal. A single case report of 'lung bleeding' after infliximab treatment for GVHD was found in the literature. 15 Pulmonary hemorrhages seen in our patients were attributable to their prolonged treatment of severe, refractory GVHD exacerbated by GVHD-induced cytokine damage and/or infection. The latter has been described with acute GVHD and idiopathic pneumonia syndrome. 38 
Conclusion
This retrospective pediatric case series using infliximab for severe GVHD demonstrates clinical activity, but the durability of responses was poor. Infliximab appeared to allow transient control of some very difficult and advanced cases of GVHD, and perhaps prolonged survival. The favorable toxicity profile, even following its prolonged use in the setting of severe GVHD, makes infliximab an attractive agent to evaluate in prospective clinical prophylactic and/or therapeutic GVHD trials. However, the optimal dosage of infliximab has not been defined. The Pediatric Blood and Marrow Transplant Consortium recently published the results of a prospective pilot trial in pediatric subjects investigating the pharmacokinetics of infliximab in children with steroid-refractory GVHD involving the gastrointestinal tract. 25 Insight gained from this trial may help guide the design of future clinical trials aimed to determine the optimal infliximab dosing regimen for GVHD.
